Anticoagulant prophylaxis in medical patients: An objective assessment

Pharmacotherapy

Volumn 24, Issue 8 II, 2004, Pages

  Deitelzweig, Steven ^a,e   Groce III, James B ^b,c,d  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MOSES H CONE MEMORIAL HOSPITAL   (United States)

^d CAMPBELL UNIVERSITY   (United States)

^e JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Anticoagulant prophylaxis; Deep vein thrombosis; Low molecular weight heparins; Pulmonary embolism; Unfractionated heparin; Venous thromboembolism; VTE risk factors

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; ESTROGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN;

AGING; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; BLEEDING; CANCER PATIENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSFIBRINOGENEMIA; ESTROGEN THERAPY; HEART FAILURE; HEART INFARCTION; HEMATOMA; HIGH RISK PATIENT; HUMAN; IMMOBILIZATION; INJECTION SITE; LOW DRUG DOSE; LUNG EMBOLISM; MULTICENTER STUDY; OBESITY; PRACTICE GUIDELINE; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; SURGICAL PATIENT; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS PREVENTION;

FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; VENOUS THROMBOSIS;

EID: 3543087296     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.12.120S.36115     Document Type: Conference Paper

References (31)

1. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992;305:567-74.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991;115:591-5.
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT study. Arch Intern Med 1991;151:933-8.
4. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17:259-70.
5. Goldhaber SZ, Visini L, DeRosa M. Acute pulmonary embolism: clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER). Lancet 1999;353: 1386-9.
6. Goldhaber SZ, Morpurgo M. Diagnosis, treatment, and prevention of pulmonary embolism: report of the World Health Organization/International Society and Federation of Cardiology task force. JAMA 1992;268:1727-33.
7. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
8. Deitelzweig SB, Vanscoy GJ, Niccolai CS, Rihn TL. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients. Ann Pharmacother 2003;37: 402-11.
9. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-19.
10. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients with enoxaparin study group. N Engl J Med 1999;341:793-800.
11. Conceptis Technologies, Inc. PREVENT: dalteparin cuts VTE for immobilized patients. Available from http://www.theheart. org/documents/page.cfm? from= 590001200&doc_id=34112. Accessed February 10, 2004.
12. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl):132S-75.
13. Tapson V, Elliot G, Turple AGG, et al. Suspicions and subtleties in venous thromboembolism: are clinical models and strategies effective? Med Crossfire 2000;2:34-95.
14. Goldhaber SZ, Tapson VF. DVT-free. Presented at the XIXth International Society of Thrombosis and Haematosis Congress, Birmingham, England, July 12-18, 2003.
15. Gensini GF, Prisco D, Falciani M, Comeglio M, Colella A. Identification of candidates for prevention of venous thromboembolism. Semin Thromb Hemost 1997;23:55-67.
16. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomised double-blind trial. Haemostasis 1986;16:159-64.
17. Muntz JE. Prevention of thromboembolic complications in the rehabilitation center: diagnostic and risk factor stratification tools. Am J Phys Med Rehabil 2000;29(suppl):S17-21.
18. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001;38(suppl 5):12-19.
19. Garlund B. Randomised, controlled trial of low-dose heparin for prevention of pulmonary embolism in patients with infectious diseases: the heparin prophylaxis study group. Lancet 1996;347:1357-61.
20. Menzin J, Richner R, Huse D, et al. Prevention of deep-vein-thrombosis following total hip replacement surgery with enoxaparin vs. unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994;28:271-5.
21. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982;96:561-5.
22. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982;10(7):448-50.
23. Belch JJ, Lowe GD, Ward AG, Forbes CD, Prentice CR. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981;26:115-17.
24. Ibarra-Perez C, Lau-Cortes E, Colmenero-Zubiate S, et al. Prevalence and prevention of deep venous thrombosis of the lower extremities in high-risk pulmonary patients. Angiology 1988;39:505-13.
25. Lechler E, Schramm W, Flosbach CW, et al. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low molecular weight heparin (enoxaparin). The PRIME (prophylaxis in internal medicine with enoxaparin) study group. Haemostasis 1996;26(suppl 2):49-56.
26. Kleber FX, Witt C, Flosbach CW, et al. Study to compare the efficacy and safety of the LMWH enoxaparin and standard heparin in the prevention of thrombotic events in medical patients with cardiopulmonary diseases [abstr]. Am Hematol 1998;76:261.
27. Harenberg J, Shomacker U, Flosbach CW, Spiro T. Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical patients at increased risk of thromboembolism [abstr]. Blood 1999;94(suppl 1):399a.
28. Hillbom J, Enla T, Flosbach CW, et al. Enoxaparin, a low molecular weight heparin, is superior to heparin in patients with acute atherothrombotic stroke [abstr]. Stroke 1998;29:304.
29. Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness: the enoxaparin in medicine study group. Thromb Haemost 1996;76:529-34.
30. Carroll DN, Hudson EB. Venous thromboembolism prophylaxis conversion in nonsurgical inpatients. Ann Pharmacother 2003;37:1194-6.
31. Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 2000;118:1680-4.